Biomarker-Led Trials Emerge as Key Strategy for Precision Psychiatry Development
Key Insights
Pharmaceutical sponsors are increasingly adopting biomarker-driven clinical trials in psychiatry to overcome the subjectivity of traditional patient-reported and clinician-rated endpoints.
HMNC Brain Health (search) is developing a vasopressin 1b inhibitor (search) with genetic testing to identify patients most likely to benefit from the therapy, representing a shift toward personalized psychiatric treatment.
Regulatory agencies are showing flexibility toward biomarker-led trial designs, though challenges remain in balancing patient population size with treatment specificity.
Biomarker-led clinical trials are gaining momentum in psychiatric drug development as sponsors seek more objective methods to identify patients who will respond to treatment, moving away from traditional subjective endpoints that have proven challenging to interpret.
Dr. Hans Eriksson, Chief Medical Officer at HMNC Brain Health (search) and a seasoned psychiatry and drug development expert, explains that psychiatric drug developers have long struggled to find baseline characteristics that predict treatment response. "The results up to now have been quite bleak, so something more drastic needs to be done to identify patients who will benefit from treatment," Eriksson said.
Genetic Testing Guides Treatment Selection
The shift toward biomarker-driven approaches is particularly relevant for depression (search), which is often hereditary. By examining patients' genetic makeup, which remains consistent throughout their lives, researchers can develop biomarkers that more accurately predict positive treatment responses.
HMNC Brain Health (search) exemplifies this approach with their development of a vasopressin 1b inhibitor (search), originally developed by Sanofi. The company has created a genetic test focused on components of vasopressin signaling (search) that can identify patients likely to achieve better outcomes from the therapy. "While this medicine has already demonstrated a strong efficacy signal, it seems that our genetic test is able to identify a subset of individuals who are likely to obtain better outcomes from the therapy," Eriksson noted.
The vision involves clinicians making diagnoses and conducting genetic tests to determine which therapy has the highest likelihood of benefiting specific patients. While this approach won't provide absolute certainty, it enables more informed treatment decisions.
Trial Design and Regulatory Considerations
Biomarker-led trials can be conducted in two ways: assessing biomarkers before trials to assign patients to treatments, or analyzing biomarkers post-study to understand their contribution to treatment effects. However, regulators are cautious about using non-validated biomarkers for patient assignment.
HMNC Brain Health (search) has conducted trials in large patient cohorts, analyzing biomarkers after completion. "While the trial was ongoing, no one knew the characteristics of each patient, and we did not use biomarkers to assign individuals to a certain treatment arm," Eriksson explained. "In the current regulatory climate, I think that's the way one has to do it."
Implementation Challenges
Despite the promise of precision psychiatry, practical challenges remain. Genetic testing takes approximately three weeks to determine if a patient is suitable for treatment, and sponsors must balance sensitivity and specificity to identify reasonably sized patient cohorts that will benefit meaningfully from treatment.
"It's about finding some sort of sweet spot and thinking about what can be done to enhance treatment outcomes over the standard of care without losing too many from the addressable population," Eriksson said.
Regulatory Flexibility and Approval Pathways
Regulatory agencies are demonstrating increased flexibility toward biomarker-led trial designs. In the United States, new antidepressants can secure approval based on two positive short-term trials lasting six to eight weeks, with long-term studies required as post-approval commitments. European regulators typically require long-term data before approval, resulting in delayed patient access but providing documented proof of long-term benefit.
Industry Renaissance in Psychiatric Drug Development
The psychiatric drug development landscape is experiencing what Eriksson describes as a second golden age, following the first in the 1950s when initial antipsychotic, antidepressant, and anxiolytic medications were developed. This current renaissance is driven by smaller companies and startups exploring psychedelic medicines like psilocybin and LSD that were previously abandoned.
However, the initial enthusiasm around psychedelics, based on high efficacy in early studies, has not consistently materialized in larger clinical trials, with functional unblinding remaining a significant challenge.
The recent introduction of Johnson & Johnson's Spravato (esketamine) for treatment-resistant depression (search) has challenged conventional understanding in the depression (search) field. Traditional knowledge suggested patients needed four to six weeks of treatment before seeing efficacy, but Spravato can help some patients feel better within a day of treatment.
Future of Precision Psychiatry
The integration of genetic guidance with non-drug approaches like cognitive behavioral therapy represents the optimal treatment strategy. While biological markers offer significant potential, external factors continue to influence psychiatric disorders (search), meaning biomarkers alone cannot completely solve treatment prediction challenges.
As the field advances, the success of biomarker-led trials will depend on finding the right balance between identifying patients who will benefit from treatment while maintaining sufficiently large addressable populations for commercial viability.